Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03028675 · ClinicalTrials.gov registry record
pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 4
- Enrollment target
NCT03028675: Completed study, sponsored by NYU Langone Health.
NCT03028675 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03028675 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
Study Summary
Twenty subjects (10 patients and 10 age-matched control volunteers) will be recruited for this study. MRI scans will take place on a 3T MRI Scanner (Skyra or Prisma, Siemens Medical Solutions) located at The NYU Center for Biomedical Imaging. MRI scans will consist of a 1-hour brain scan for both patients and controls. In the first 6 months of the study, investigators will develop and test a uMT-based APT imaging for brain tissue pH measurement and use a hypercapnia paradigm to validate the tissue pH changes between breathing room air and 5% CO2 (by increasing tissue acidity) inhalation. With implementation of hypercapnia MRI, pH-weighted imaging will be validated for its robustness and reproducibility.
Primary Outcome
The pH will be estimated based on the calibration methods of quantification of exchange as a function of saturation time (QUEST)32 and its ratiometric analysis (QUESTRA) 33.
Interventions
- OTHER MRI Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2018-08-10 |
What the finished NCT03028675 record still lists
NCT03028675 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which MRI Scan is the first listed.
NCT03028675 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03028675 about?
NCT03028675 is a clinical study titled "pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress". Twenty subjects (10 patients and 10 age-matched control volunteers) will be recruited for this study. MRI scans will take place on a 3T MRI Scanner (Skyra or Prisma, Siemens Medical Solutions) located at The NYU Center for Biomedical Imaging. MRI scans will consist of a 1-hour brain scan for both pa...
What is the current status of trial NCT03028675?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2017-05-01. Estimated completion is 2018-08-10.
What interventions are being tested in trial NCT03028675?
The interventions under investigation include: MRI Scan (OTHER).
Who is sponsoring clinical trial NCT03028675?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI